Artificial intelligence is quickly moving beyond testing into core pharmaceutical processes. AI-based applications can support document processing, quality workflows, manufacturing analysis, clinical research, pharmacovigilance, laboratory activities, and other data-heavy processes.
However, when an AI system changes in a GxP-controlled process, innovation is not enough. Companies must demonstrate that the technology remains fit for its intended purpose and that risks to patient safety, product quality, and data integrity are properly managed. That is where AI validation in pharma becomes critical.
Conventional computerized systems tend to run based on pre-determined logic. AI also introduces other issues because system performance may depend on training data, model design, context of use, settings, and even changing real-world data.
Contemporary guidance is thus shifting toward lifecycle-based and risk-based methods, rather than equal validation effort for every function.
The GAMP Guide on Artificial Intelligence, released in 2025 by ISPE, specifically covers AI-enabled computerized systems in GxP territory and prioritizes risk-oriented activities, continuous control, supplier collaboration, and lifecycle management.
You don’t need to test everything equally for GxP AI validation. First, organizations must define what the AI system is and where it sits, the decisions it can affect, and what might happen if the system produces an incorrect finding.
This aligns with the overall risk-driven trend of GAMP 5, which emphasizes critical thinking and proportional controls for computerized systems rather than unnecessary validation activity.
Start by capturing what the AI-enabled system is supposed to do.
They should include knowledge of users, inputs, outputs, business process, GxP relevance, system limits, dependencies, and whether humans review or act on its recommendations.
A vague intended use creates vague validation. Specific requirements let teams focus testing and controls where they’re needed.
Not every AI application a pharmaceutical company uses requires the same validation method.
Evaluate how the system may impact patient safety, product quality, data integrity, regulatory records, manufacturing decisions, laboratory results, or other regulated processes.
Stronger assurance activities should reflect higher potential impact.
An AI risk assessment should be structured to address both the traditional computerised system risks and AI-related issues.
Potential areas include:
The objective is not to create the most extensive risk register. It is to identify risks that may significantly impact the GxP process and implement material controls.
Ai should not be given approval because it seems to work in the event of demonstrations.
Organizations require a set of established acceptance criteria to suit the purpose. Tests should reveal whether a system is reliable under controlled conditions of operation including any significant failure modes where appropriate.
Many AI-enabled GxP systems may have human oversight as a critical control.
Companies must establish when human judgment is necessary, who may approve or disapprove AI-generated suggestions, how doubtful results are escalated, and which choices must remain within the discretion of qualified human judgment.
The value of testing does not mean that the more you test, the more valid your results are. The less dumb goal is to produce enough evidence that the system can be relied upon for its GxP application.
The existing Computer Software Assurance guidance of FDA on the production and quality management system software of medical devices also outlines a risk-based framework of developing confidence in automation and where further rigor is necessary.
Functionalities that can impact critical GxP results should be tested more rigorously than non-critical administrative aspects.
This puts resources where failure will have the greatest consequences.
The ideal inputs should not be used but the test scenarios should reflect actual users, representative data, the expected workflows, system interfaces and reasonably foreseeable failure conditions.
Challenge the AI model with realistic, unusual, incomplete, and edge-case inputs to evaluate its behavior, while separately testing how the AI feature functions within the GxP application.
Documentation must offer cognizant presentation of assurance as opposed to it being an objective in itself. The level of evidence should be dictated by risk, intended use, and system complexity.
When integrated into a suitable controlled environment, repeatable automated testing and monitoring can reduce manual effort, improve consistency, and enable faster release cycles.
Testing an AI-enabled GxP application requires more than testing whether the underlying model produces acceptable results. LLM and AI model testing focuses on the model’s behavior and performance, while AI feature and functionality testing evaluates how the model operates within the pharmaceutical application.
These are related but separate testing layers. A model may perform well in isolation, but the application that uses it can introduce problems through prompts, workflows, interfaces, permissions, data handling, output presentation, or business logic.
LLM model testing focuses on the behavior of the underlying large language model or AI model. Depending on the intended use, testing may examine response accuracy, consistency, relevance, hallucinations, robustness, bias, inappropriate outputs, prompt sensitivity, context handling, and behavior across representative and challenging inputs.
For a regulated use case, teams should establish acceptance criteria that reflect the intended purpose rather than relying only on general model benchmarks.
AI feature testing focuses on the specific AI capability implemented within the GxP application.
For example, if an application uses an LLM to summarize deviation records, the testing should determine whether the summarization feature correctly receives the approved data, generates an appropriate output, displays the result correctly, preserves required records, and supports the intended workflow.
The model may be technically capable, but the feature still needs to work correctly within the regulated application.
Functionality testing evaluates how the AI capability interacts with the rest of the application.
Testing may include user permissions, input validation, workflow routing, approvals, integrations, audit trails, data transfer, error handling, output storage, notifications, and other application functions.
This is particularly important when an AI output becomes part of a GxP workflow or influences a regulated decision.
A practical validation strategy should distinguish between model-level testing and application-level testing.
Model testing asks: “Does the AI model behave appropriately for its intended purpose?”
Application testing asks: “Does the AI feature work correctly and safely within the GxP application?”
Both questions matter. Testing only the model does not show that the complete application is fit for its intended use, while testing only the application’s buttons and workflows may miss weaknesses in the underlying AI behavior.
After model-level and feature-level testing, organizations should also perform appropriate end-to-end testing.
This can evaluate how user inputs move through the application, how the AI processes information, how outputs are generated and presented, what users can do with those outputs, and how relevant records and evidence are maintained.
For GxP applications, the final validation strategy should therefore consider AI model testing, AI feature testing, AI functionality testing, integration testing, and end-to-end application testing, based on the system’s risks and intended use.
Reaching go-live is not the end of AI system validation. Organizations need lifecycle controls to ensure the system continues to run suitably post-deployment.
The organization must know the approved model and configuration and the components used in the production environment. The organization must identify, assess, and control changes.
Information used to create, test, or run an AI system must be handled based on its purpose and the risks it presents. Appropriate controls may include provenance, quality, integrity, access, and suitability.
Organizations are expected to identify meaningful indicators that identify unexpected deterioration or changes in model performance where monitoring is applicable to the system.
Any model changes, updates to new data, configuration changes, integrations, and significant changes to the intended purpose should trigger a suitable impact assessment and determine whether further assurance activities are necessary.
Periodic review helps ensure the system remains fit for its intended use, relevant controls remain in effect, and new risks or operational changes are managed accordingly.
Between compliance and innovation, the biggest mistake companies can make is choosing one over the other. An effective validation program should support both.
The ISPE GAMP AI guidance offers risk-based strategies to support efficient, compliant processes and enable continuous control and improvement of AI-enabled computerised systems.
| Traditional Bottleneck | Smarter AI Validation Approach |
| Validate everything equally | Prioritize by GxP risk |
| Excessive scripted testing | Use appropriate risk-based testing |
| Validation starts near go-live | Build assurance into development |
| Documentation drives activity | Risk and intended use drive evidence |
| Quality works separately | QA, IT, business and data teams collaborate |
| One-time validation mindset | Maintain lifecycle oversight |
| Every change triggers major effort | Assess change based on impact |
This strategy does not imply lessening compliance. It means allocating validation resources to the controls and evidence that matter.
Successful AI compliance in pharma requires expertise across multiple fields. Traditional validation knowledge remains essential, but organizations need specialists who understand the new technology and can translate regulatory requirements into practical controls.
Professionals are expected to be aware of the rules of Computer System Validation and Computer Software Assurance, as well as the current risk-based methods.
Validation teams do not always have to turn into data scientists, although they must be aware of basic AI concepts, model behavior, data relations, and constraints, and have some knowledge of the lifecycle risks.
Risk-based thinking helps teams distinguish critical AI functionality from less important features and decide how to allocate validation effort.
AI validation experts should create meaningful tests based on intended use, performance requirements, failure modes, data conditions or requirements, and any pertinent GxP risks.
Effective AI validation requires interdependence among trusts, validation, data science, engineering, IT, and business process owners, as well as cybersecurity teams and technology vendors.
The potential of AI in pharmaceutical manufacturing, quality, laboratories, clinical operations, pharmacovigilance, and other regulated functions is enormous. However, implementing AI within a GxP process cannot be done by simply proving that a model yields impressive results.
The initial steps to effective AI validation in pharma include defining intended use, assessing GxP impact, conducting risk assessments, ensuring proper testing, establishing data governance, maintaining human oversight, managing change control, and continuously monitoring performance.
Maximum documentation should not be the aim. It must provide adequate, justifiable evidence that an AI-based system can be used in the intended regulated fashion without endangering patient safety, product quality, or data integrity.
As the industry becomes more heavily invested in AI, companies will need more tech- and compliance-savvy professionals. Pharma Connections can support this transition by providing GxP validation services, software testing, experienced validation resources, staffing solutions, audit preparation services, and training to help professionals build knowledge of the next generation of pharmaceutical validation.
AI validation in pharma is the process of creating and sustaining evidence that an AI-enabled system is fit for its intended use in GxP.
AI implementation can add factors such as training and operational data, model performance, explainability, bias, drift, and evolving behaviour, which require validation strategies tailored to the specific AI use case.
A pragmatic structure must consider intended use, GxP impact, risk assessment, data governance, performance criteria, testing, human oversight, supplier controls, change management, monitoring, and periodic review.
No. The level of validation must match the intended use, system complexity, GxP impact, and potential risks to patient safety, product quality, and data integrity.
Pharma Connections assists organizations with validation expertise, GxP software testing, CSV and CSA resources, staffing, audit and inspection readiness, and emerging AI validation capabilities in regulated technology settings.
Pharmaceutical validation teams don’t always need the same resources year-round. A business might be adequately…
Pharmaceutical manufacturing and regulated technology environments are increasingly shifting toward artificial intelligence, but implementing an…
Pharma and life sciences companies are managing technology environments that just keep getting more complex.…
Call/WhatsApp : +91 - 86608 77518
Email: info@pharmaconnections.in
Pharma Connections (A Product of Eduteq Connections Pvt Ltd),
Membership No.: 459, WeWork Salarpuria Symbiosis, Arekere Village, Begur Hobli, Bannerghatta Road, Bengaluru, Karnataka – 560076
Pharma Connections, Established on February 14, 2019, A Product of Eduteq Connections Pvt Ltd (An ISO 9001:2015 certified company), is dedicated to providing training and upskilling opportunities for Life science Professionals.
Read More
